Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 3, 2012, Pages 234-243

  Kamat, Anupa ^a   Lyons, Jennifer L ^a   Misra, Vikas ^a   Uno, Hajime ^a   Morgello, Susan ^b   Singer, Elyse J ^c   Gabuzda, Dana ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; cerebrospinal fluid; HIV; HIV associated neurocognitive disorders; immune activation

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTIGENS, CD14; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINES; COGNITION; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; NEUROPSYCHOLOGICAL TESTS; RNA, VIRAL; VIRAL LOAD;

EID: 84864293796     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318256f3bc     Document Type: Article

References (54)

1. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24:1367-1370.
2. McArthur JC, Steiner J, Sacktor N, et al. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699-714.
3. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136-142.
4. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-273.
5. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. plos one. 2008;3:e2516.
6. Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis. 2001;184:699-706.
7. Gartner S, Liu Y. Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol. 2002;8:69-75.
8. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69-81.
9. Gras G, Kaul M. Molecular mechanisms of neuroinvasion by monocytesmacrophages in HIV-1 infection. Retrovirology. 2010;7:30.
10. Kaul M, Zheng J, Okamoto S, et al. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 2005;12 (suppl 1):878-892.
11. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol. 1997;42: 679-688.
12. Enting RH, Foudraine NA, Lange JM, et al. Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol. 2000;102: 216-221.
13. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol. 1997;42:689-698.
14. Brew BJ, Pemberton L, Cunningham P, et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997;175:963-966.
15. Cinque P, Vago L, Mengozzi M, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. 1998;12:1327-1332.
16. Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA. 1998;95:3117-3121.
17. Kelder W, McArthur JC, Nance-Sproson T, et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44:831-835.
18. Sanders VJ, Pittman CA, White MG, et al. Chemokines and receptors in HIV encephalitis. AIDS. 1998;12:1021-1026.
19. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084-2090.
20. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol. 1990;28: 556-560.
21. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferongamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41:69-74.
22. Shaskan EG, Brew BJ, Rosenblum M, et al. Increased neopterin levels in brains of patients with human immunodeficiency virus type 1 infection. J Neurochem. 1992;59:1541-1546.
23. Wiley CA, Achim CL, Schrier RD, et al. Relationship of cerebrospinal fluid immune activation associated factors to HIV encephalitis. AIDS. 1992;6:1299-1307.
24. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest. 1993;91:2769-2775.
25. Mastroianni CM, Paoletti F, Valenti C, et al. Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry. 1992;55:219-221.
26. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63: 213-221.
27. Eden A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after .4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196:1779-1783.
28. Cysique LA, Brew BJ, Halman M, et al. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr. 2005;39:426-429.
29. Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.
30. Yilmaz A, Price RW, Spudich S, et al. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:168-173.
31. Lyons JL, Uno H, Ancuta P, et al. Plasma SCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr. 2011;57:371-379.
32. Fischer-Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14 +CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol. 2001;7:528-541.
33. Chang L, Ernst T, St Hillaire C, et al. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther. 2004;9:431-440.
34. Letendre SL, Zheng JC, Kaul M, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17:63-69.
35. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789-1799.
36. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol. 2004;26:759-778.
37. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001;2:RESEARCH0032.
38. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98:31-36.
39. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010;5:e9166.
40. Xia J, Psychogios N, Young N, et al. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009; 37:W652-W660.
41. Bijlsma S, Bobeldijk I, Verheij ER, et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem. 2006;78:567-574.
42. Burdo TH, Katner SN, Taffe MA, et al. Neuroimmunity, drugs of abuse, and neuroAIDS. J Neuroimmune Pharmacol. 2006;1:41-49.
43. Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev. 2009; 19:215-231.
44. Nath A, Maragos WF, Avison MJ, et al. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol. 2001;7:66-71.
45. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
46. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18:45-55.
47. Gisolf EH, van Praag RM, Jurriaans S, et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:426-433.
48. Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferongamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol. 2005;168:154-163.
49. Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry. 2008;20:73-88.
50. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008;47:544-552.
51. Schmidtmayerova H, Nottet HS, Nuovo G, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci USA. 1996;93:700-704.
52. Letendre SL, Lanier ER, McCutchan JA. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J Infect Dis. 1999;180: 310-319.
53. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25:625-633.
54. Farag NH, Rashed HA, Hassan M, et al. Hepatitis C infection, cognition, and inflammation in an Egyptian sample. J Med Virol. 2011;83:261-266.